Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2020-06-30 / Expert Rev Anticancer Ther 2020 Aug;20(8):639-646Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo
/in Colorectal Cancer, International Publications, Newcastle Disease Virus /von 2020-06-29 / Cancer Cell Int. 2020;20:278Newcastle disease virus suppress glycolysis pathway and induce breast cancer cells death
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2020-06-27 / Virusdisease 2020 Sep;31(3):341-348CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-06-24 / Mol Ther Oncolytics 2020 Sep;18:295-303Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2020-06-21 / J Control Release 2020 Jun;326:63-74Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy
/in Dendritic Cells, International Publications /von 2020-06-15 / Nanomedicine 2020 Jun;29:102240Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses
/in Hyperthermia, International Publications /von 2020-06-12 / Front Oncol 2020;10:819Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion
/in Glioblastoma, International Publications, Newcastle Disease Virus /von 2020-06-05 / Cells 2020 Jun;9(6)IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
/in IOZK Veröffentlichungen /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution